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Sommario 
Il virus di Epstein-Barr (EBV) è coinvolto nello sviluppo di un ampio spettro di malattie 
linfoproliferative, in particolare nei soggetti immunocompromessi. Oltre all’immunodepressione, 
l’attivazione immunitaria cronica può indurre la stimolazione della cellula B, promuovendo 
l’espansione delle cellule infettate da EBV. I fattori che possono contribuire all’attivazione e 
all’espansione delle cellule B infettate da EBV, anche nei soggetti con infezione da HIV-1, sono per 
lo più sconosciuti. In Africa l’infezione primaria da EBV insorge durante la prima infanzia e i 
linfomi associati ad EBV sono un'importante causa di morbidità e mortalità nei bambini. Elevati 
livelli di EBV costituiscono un fattore di rischio per l’insorgenza dei tumori associati al virus. Ad 
oggi, non sono disponibili dati circa l’infezione da EBV e le patologie associate nei bambini 
africani con infezione da HIV-1. La mancanza di questi dati è in parte dovuta alla difficoltà di 
analisi di laboratorio nei Paesi in via di sviluppo. L'utilizzo di Dried Blood Spot (DBS) potrebbe 
rappresentare un metodo semplice per raccogliere, conservare campioni di sangue, e consentire il 
loro trasporto in laboratori specializzati. 
Gli scopi della ricerca svolta durante il corso di Dottorato sono stati i seguenti: 
1) studiare la relazione tra viremia di EBV e marcatori di attivazione immunitaria nei soggetti con 
infezione da HIV-1.  
2) studiare l’infezione da EBV nei bambini africani con infezione da HIV-1 e/o con tumori EBV-
correlati.  
3) sviluppare una nuova applicazione di DBS per la rilevazione della clonalità delle cellule B, per 
la diagnosi e il monitoraggio della patologia neoplastica. 
 
1) Viremia di EBV e attivazione immunitaria in soggetti con infezione da HIV-1 
Nello studio sono stati inclusi 156 pazienti con infezione da HIV-1. 85 pazienti erano in terapia 
antiretrovirale (ART). Il DNA di EBV è stato rilevato in 114 pazienti, e in tutti i casi tranne 3 era 
EBV tipo 1. I livelli mediani di EBV-DNA erano di 43[1-151] copie/105 cellule. I livelli di EBV 
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erano più elevati nei soggetti con plasmaviremia di HIV-1 rilevabile, nonostante un buono stato 
immunologico (CD4>500 cellule/µl), rispetto a pazienti con plasmaviremia di HIV-1 non rilevabile, 
indipendentemente dallo stato immunologico (46[5-136] vs 17[1-56] copie/105 cellule, p=0.008). 
Pazienti con alti livelli di EBV-DNA (> valore mediano) avevano livelli più alti di lipopolisaccaride 
batterico (LPS) e di citochine proinfiammatorie (IL-6, IL-10 e TNF-α) rispetto a pazienti con bassa 
viremia di EBV. Inoltre, la percentuale di cellule B attivate correlava con i livelli di EBV (r=0.754; 
p<0.001). Nell'insieme, questi dati indicano una significativa associazione tra plasmaviremia di 
HIV-1, marcatori di attivazione immunitaria e citoviremia di EBV e suggeriscono che la persistenza 
di HIV-1 e l’attivazione immunitaria, indipendentemente dalla ripopolazione dei linfociti CD4 
periferici, possono favorire l’espansione delle cellule B infettate con EBV. 
 
2) Associazione tra livelli di EBV e NHL nei bambini della Tanzania e parametri relativi a EBV nei 
bambini con infezione da HIV-1 in Uganda  
E' stato condotto uno studio caso-controllo in bambini con linfomi non-Hodgkin (NHL) ammessi in 
tre centri clinici della Tanzania e controlli comparabili per età. I campioni di sangue sono stati 
raccolti in DBS. Ventuno di 35 (60%) pazienti con NHL e solo 21 di 70 (30%) controlli avevano 
EBV rilevabile nel sangue periferico (OR=4.77 [95% CI 1.71–13.33], p=0.003). Inoltre, i livelli di 
EBV erano più alti nei casi NHL rispetto ai controlli EBV-positivi (p=0.024). Nell'insieme, questi 
dati indicano che la viremia di EBV nel sangue periferico potrebbe avere rilevanza diagnostica. 
 
In un  secondo studio, i campioni di sangue di 213 bambini con infezione da HIV-1 sono stati 
raccolti su DBS presso l’ospedale Nsambya, in Kampala, Uganda. Novantadue di 140 (66%) 
bambini in ART e 57 di 73 (78%) naive sono risultati positivi per EBV. In un'analisi multivariata 
per CD4 Z-score, età e stadio WHO, bambini in ART avevano minori probabilità di avere EBV 
rilevabile rispetto ai bambini naive (OR=0.39 [95% CI 0.16-0.94], p=0.036). La viremia di EBV era 
significativamente più elevata nei bambini naive rispetto a quelli in ART (4.22 [3.87-4.58] vs 3.99 
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[3.55-4.33] log10 copie/ml; p=0.016). I livelli di 16S rDNA, utilizzato come marcatore di 
traslocazione microbica, erano significativamente più elevati nei bambini naive rispetto a quelli in 
ART (2.16 [2.11-2.28] vs 2.09 [2.02-2.22] log10 copie/µl; p=0.007) e correlavano con i livelli di 
EBV-DNA (r= 0.382, p=0.016), suggerendo che i prodotti microbici circolanti promuovono 
l’attivazione e l’espansione della cellula B infettata da EBV. Il trattamento con ART, probabilmente 
limitando la viremia di HIV-1 e la conseguente attivazione immunitaria, può ridurre la replicazione 
di EBV e l’espansione delle cellule infettate da EBV. 
 
3) Rilevabilità delle popolazioni clonali B da campioni di DBS: uno strumento per la diagnosi e il 
monitoraggio dei tumori delle cellule B 
In primo luogo, utilizzando campioni di sangue di diversa origine, è stato verificato che i DBS 
contenessero un numero sufficiente di linfociti per stimare la clonalità senza ottenere risultati falsi 
positivi. Mediante l'impiego di cellule Namalwa, che contengono 2 copie di EBV/cellula, è stata 
trovata una ottima correlazione tra i risultati attesi e le copie di EBV rilevate (r=0.987, p<0.0001); si 
è potuto quindi stabilire che una popolazione clonale B è rilevabile su DBS quando sono presenti 
almeno 200 cellule clonali nel campione analizzato. Inoltre, sono stati ottenuti risultati molto simili 
per la clonalità cellulare analizzando il DNA ottenuto da DBS e da sangue fresco di pazienti con 
leucemia linfatica cronica. Questo studio, dimostrando che è possibile valutare la clonalità su 
campioni di sangue conservato su DBS, allarga le opzioni diagnostiche e di monitoraggio. 
 
Conclusioni  
In questi studi abbiamo trovato una relazione significativa tra marcatori di traslocazione microbica, 
livelli di citochine pro-infiammatorie e livelli di EBV-DNA negli adulti e nei bambini con infezione 
da HIV-1. Di interesse e  in accordo con studi precedenti, abbiamo anche dimostrato che i livelli di 
EBV sono più elevati nei pazienti con aumento di linfociti CD4 ma incompleta soppressione della 
viremia di HIV-1 rispetto a pazienti con plasmaviremia non rilevabile, indipendentemente dal 
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numero di linfociti CD4. Nell'insieme, questi dati suggeriscono che l'attivazione immunitaria 
indotta da HIV-1 può risultare nella stimolazione e nell’espansione delle cellule B infettate con 
EBV, un fattore di rischio per lo sviluppo di neoplasie EBV-associate.  
La relazione tra attivazione immunitaria e livelli di EBV è risultata anche negli studi effettuati nei 
bambini con infezione da HIV-1, dove abbiamo trovato che i livelli di EBV-DNA e di 16S rDNA 
erano significativamente più elevati nei bambini in ART rispetto a quelli naive. Il trattamento con 
ART, probabilmente limitando l’attivazione immunitaria, potrebbe prevenire la stimolazione della 
cellula B e l’espansione della cellula B. Queste osservazioni possono essere di particolare interesse 
anche per pianificare strategie terapeutiche nei soggetti con infezione da HIV-1. 
Inoltre, la dimostrazione che i linfomi NHL sono significativamente associati ad elevati livelli di 
EBV nel sangue periferico, suggerisce che la determinazione di EBV nel sangue  potrebbe avere 
una rilevanza diagnostica e prognostica per le neoplasie delle cellule B associate ad EBV. In questo 
contesto abbiamo potuto stimare che i campioni di DBS  sono anche idonei ad identificare la 
presenza di una popolazione clonale B. Questo è importante perché estende le opzioni di diagnosi e 
monitoraggio dei linfomi B anche dove non sono di facile accesso queste analisi. 
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Summary 
Epstein-Barr Virus (EBV) is involved in a wide range of malignancies, particularly in 
immunocompromised subjects. Besides immunodepression, chronic immune activation may induce 
B-cell stimulation leading to an expansion of EBV-infected cells,  thus increasing the risk of EBV-
related malignancies. The factors that may contribute to HIV-1-induced B cell activation and 
expansion of EBV-infected cells are largely unknown. In Africa EBV primary infection occurs 
during infancy and early childhood and EBV-associated lymphomas represent an important cause of 
morbidity and mortality in children. High levels of EBV represent a risk factor for the onset of 
EBV-related malignancies. To date, no data are available about EBV-infection and related 
malignancies in the context of HIV-1 infection in African children; this may be partly due to lack of 
access of laboratory analyses in developing countries. The use of Dried Blood Spot (DBS) may 
represent an easy method to collect and store blood samples and allow their reliable transport to 
specialized laboratories. 
My PhD research focused on the following themes: 
1) the relationship between markers of immune activation and EBV load in HIV-1 infected patients.  
2) EBV infection in HIV-1 infected and uninfected children in African countries.  
3) a new application of Dried Blood Spot to type and quantify EBV and to identify B cell clonality 
in order to diagnose and monitor B-cell malignancies. 
 
1) EBV load and immune activation in HIV-1-infected patients 
A total of 156 HIV-1-infected patients were included in this study, 85 of which were under 
antiretroviral therapy (ART). EBV-DNA was detected in 114 patients, and in all but 3 it was EBV 
type 1. The median [interquartile] EBV-DNA load was 43[1-151] copies/105 cells and it was higher 
in patients with detectable HIV-1 plasma viremia, despite good immunological status (CD4>500 
cells/µl), than in patients with undetectable HIV-1 plasma viremia regardless of immunological 
status (46[5-136] vs 17[1-56] copies/105 cells, p=0.008). Patients with high EBV-DNA load 
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(>median value) presented higher levels of LPS and proinflammatory cytokines (IL-6, IL-10 and 
TNF-α) than patients with low EBV load. Furthermore, percentages of activated B-cells correlated 
with EBV-DNA load (r=0.754; p<0.001). Overall, these findings indicate a strong association 
between HIV-1 viremia, markers of immune activation and EBV load, and suggest that persistence 
of HIV-1 viremia and immune activation, regardless of peripheral CD4 cell depletion/repopulation, 
may favour the expansion of EBV-infected cells. 
 
2) Association between NHL and blood levels of EBV in children in Tanzania, and dynamics of EBV 
in HIV-1-infected children in Uganda  
A matched case-control study was performed in children with Non-Hodgkin’s Lymphoma (NHL) 
admitted to three clinical centers in Tanzania, and their age-matched controls. Blood samples were 
collected on DBS. 21 out of 35 (60%) NHL patients and only 21 out of 70 (30%) controls presented 
EBV detectable in peripheral blood, thus showing a significant association between NHL and EBV 
in blood (OR=4.77 [95% CI 1.71–13.33], p=0.003). Furthermore, EBV-DNA levels were higher in 
cases compared to EBV-positive controls (p=0.024). Overall, these findings indicate that EBV-
DNA load in peripheral blood might have diagnostic relevance.  
 
In a second study, blood samples from 213 HIV-1-infected children were collected on DBS at the 
Nsambya Home Care, Kampala, Uganda. 92 out of 140 (66%) children on ART and 57 out of 73 
(78%) ART-naive children were found to be EBV-positive. After adjusting for CD4 Z-score, age 
and WHO stage, children on ART presented less odds of having detectable EBV than ART-naive  
children (OR=0.39 [95% CI 0.16-0.94], p=0.036). EBV load was significantly higher in ART-naive 
children than those on ART (4.22 [3.87-4.58] vs 3.99 [3.55-4.33] log10 copies/ml; p=0.016). Levels 
of 16S rDNA, a marker of microbial translocation, were significantly higher in ART-naive children 
than those on ART (2.16 [2.11-2.28] vs 2.09 [2.02-2.22] log10 copies/µl; p=0.007) and correlated 
with EBV-DNA levels (r=0.382, p=0.016), suggesting that circulating microbial products lead to B 
 7
cell activation and expansion of EBV-infected B cells. Treatment with ART, likely by limiting 
HIV-1 load and thus the HIV-1-driven immune activation, may restrict EBV replication and 
expansion of EBV-infected cells. 
 
3) Detection of clonal B-cell populations from DBS sampling: a tool for the diagnosis and 
monitoring of B-cell malignancies 
Firstly, through blood samples from donors, we ensured that DBS contains sufficient lymphocytes 
to perform a clonality assay without yielding false positive results. Using Namalwa cells that 
contain 2 EBV copies/cell, we found a good relationship between the expected and detected EBV-
DNA copies (r=0.987, p<0.0001) and we established that a clonal B-cell population on DBS was 
detected when there were at least 200 clonal cells in the analysed sample. Moreover, very similar 
clonal results were obtained between DNA from DBS and fresh whole blood from patients with 
chronic lymphocytic leukemia. This study demonstrated the possibility to perform clonality testing 
on DBS sampling, thus improving the diagnostic and monitoring options. 
 
Conclusions  
In these studies, we found a significant relationship between markers of microbial translocation, 
levels of pro-inflammatory cytokines and EBV-DNA levels in both HIV-1 infected adults and 
children, suggesting that cell activation driven by HIV-1 antigens may result in chronic B cell 
stimulation and expansion of EBV-infected B cells, a risk factor for the development of EBV-
related malignancies. Of interest, we found that EBV-DNA levels were higher in patients with a 
gain in CD4 lymphocytes, but incomplete suppression of HIV-1 viremia than in patients with 
undetectable plasma viremia, regardless their CD4 cell number.  
The relationship between immune activation and EBV levels was also supported by the findings in 
HIV-1 infected children in Uganda. Moreover, we found that EBV-DNA and 16S rDNA levels 
were significantly lower in children on ART than in those ART-naive, suggesting that treatment 
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with ART, likely by limiting immune activation, may prevent B cell stimulation and expansion of 
EBV-infected B cells. These observations may become particularly interesting to plan future 
therapeutic strategies in HIV-1 infected patients. 
We also found that NHLs are strongly associated with EBV load in peripheral blood, suggesting 
that high levels of EBV in blood might have diagnostic and prognostic relevance for the diagnosis 
and monitoring of EBV-related B cell malignancies. In this context we assessed that DBS sampling 
was also suitable to  identify the presence of a B cell clonal population. Our results showed it is 
possible to perform clonality testing on DBS sampling, thereby improving the diagnostic and 
monitoring capability of B cell lymphomas in resource-limited settings. 
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Introduction 
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1. Introduction 
1.1 Epstein-Barr Virus 
1.1.1 General characteristics 
Epstein-Barr Virus (EBV), also defined as Human Herpesvirus 4 (HHV4), belongs to herpesviridae 
family, gammaherpesviridae subfamily, lymphocryptovirus gender. In 1961 Burkitt described a 
lymphoma, which will be later named Burkitt’s lymphoma (BL) in his honour, that affected many 
young children in some area of Africa and New Guinea. In 1964, the two researchers, Epstein AM 
and Barr Y, isolated a virus from BL cells, namely Epstein-Barr. 
EBV presents a ubiquitary behaviour and its primary infection is usually asymptomatic, but it 
occasionally may induce a benign lymphoproliferative disorder, known as infectious 
mononucleosis. EBV starts the infection in the oropharyngeal cells permissive for viral replication. 
B lymphocytes that migrate through the oropharyngeal epithelial get infected after contact with 
them. As all herpesviruses, EBV presents a latent and a lytic cycle. In individuals that go beyond 
primary infection, the virus remains stable in B cells (about 1 infected cell per 105-106 B cells) and 
in some epithelial cells in the oropharynx. The reactivation of EBV determines the expression of 
lytic proteins, the viral replication and lysis of infected cells (Figure 1).  
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Figure 1. Interaction between Epstein-Barr virus and host cells. a. primary infection; b. 
persistent infection (from Young LS et al, 2004 modified). 
 
EBV is associated to a wide range of human tumours in vivo, nasopharyngeal carcinoma (NPC), 
endemic BL, Hodgkin Lymphoma (HL), X-linked Lymphoprolipherative Disease (XLPD), post-
transplanted lymphoprolipherative disease (PTLD), immunoblastic lymphoma (IBL) and diffuse 
large B cell lymphoma (DLBCL), arising in immunocompromised patients. In vitro, EBV shows a 
potent transforming ability, being able to efficiently induce uncontrolled proliferation of infected B 
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lymphocytes, leading to the genesis of lymphoblastic cell lines (LCLs). In tumours and in LCLs 
only latent viral proteins are usually expressed.  
 
1.1.2 Structure and genome 
EBV particles diameter measures approximately 120-200 nm. The nucleocapsid, composed of 162 
capsomeres, presents a icosahedral structure with a diameter of 100-110 nm and is surrounded by 
the tegument. The core is formed by proteins anchored to the capsid on which EBV genome is 
rolled. The EBV genome consists of a linear double stranded DNA molecule of approximately 172 
kilobase pairs (kb) and is composed by 60% of guanine and cytosine bases. EBV is composed of a 
series of 0.5 kb terminal repeats (TRs) and 3 kb internal repeat sequences (IRs). The EBV genome 
encodes for 9 genes that are expressed in latently infected cells, and for many genes that are 
expressed during the lytic phase for the production of new virions. The switch from the latent to the 
lytic cycle is determined by the activation of the BZLF1 gene, encoding for the ZEBRA protein. 
Before the virus enters the cell, the major envelope glycoprotein, gp350/220, binds to the CD21 
molecule (i.e. C3d complement receptor) on the surface of the cells. This triggers the fusion of viral 
envelope with cell membrane, allowing EBV to enter cell. After 12-16 hours of infection, the linear 
EBV genome becomes circular, and remains latent in nucleus in the form of an episome. The 
transcription programme starts beginning to the promoter Wp (Figure 2). EBV use the DNA 
polymerase II of the host cell to transcribe its genes. The first proteins encoded are the EBV nuclear 
antigen (EBNA)-LP and EBNA-2. EBNA-2 up-regulates the expression of latent membrane protein 
(LMP)-1 and LMP-2, as well as cellular proteins that contribute to the growth and transformation of 
B cells, such as CD23, CD21 and oncogenes c-frg and c-myc (Kaiser C et al, 1999). EBNA-LP 
interacts with EBNA2 and is required for the efficient outgrowth of virus-transformed B cells in 
vitro. The transcriptional activation, mediated by EBNA-2 in conjunction with EBNA-LP, is 
modulated by the EBNA-3 (-3A, -3B, -3C) family of proteins. The EBNA-1 is expressed in all virus 
infected cells and it achieves its role in the maintenance and replication of the episomal EBV 
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genome through sequence-specific binding to the origin of replication, OriP (Young LS et al, 2004). 
LMP-1 is the main transforming protein of EBV and it is essential for EBV-induced B-cell 
transformation in vitro. LMP-1 functions as a constitutively activated member of the tumour 
necrosis factor receptor (TNFR) superfamily, and activates several signalling pathways in a ligand-
independent manner. Functionally, LMP-1 mimics CD40 - a member of the TNFR superfamily - 
thus providing both growth and differentiation signals to B cells. The LMP-1 activates several 
downstream signalling pathways that contribute to the induction of various genes encoding anti-
apoptotic proteins (for example, BCL2 and A20) and cytokines, such as interleukin (IL)-1 and 
CD40L (Eliopoulos AG et al, 2001). The LMP-2 proteins, LMP-2A and LMP-2B, are not essential 
for EBV-induced B-cell transformation in vitro (Young LS et al, 2004). However, LMP-2A 
prevents reactivation of EBV from latently infected cells by blocking tyrosine kinase 
phosphorylation. Furthermore, expression of LMP-2A can drive the proliferation and survival of B 
cells in the absence of signalling through the B-cell receptor. In addition to these effects, LMP-2A 
was found to induce expression of several genes involved in cell-cycle induction, inhibition of 
apoptosis and suppression of cell-mediated immunity. The two small nonpolyadenylated (non-
coding) RNAs, EBER-1 and EBER-2, are expressed in all forms of latency. The EBERs do not 
encode proteins and are not essential for the EBV induced transformation of primary B 
lymphocytes; however, it has been suggested that EBERs might be important for viral persistence 
(Nanbo A et al, 2002), and their expression in BL cell lines might increase tumorigenicity, promote 
cell survival and induce IL-10 expression (Ruf I et al, 2000; Nanbo A et al, 2002).  
Latent viral proteins are expressed according to three patterns of latency, characteristic of different 
EBV-associated malignancies. In the latency type I only EBNA-1 is expressed, whereas in the 
latency type II, EBNA-1, LMP-1, LMP-2, and EBER are expressed. In the latency type III all the 
latency genes are expressed (Table 1).  
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Table 1. Expression of EBV latent genes in diseases 
Pattern 
of 
latency 
EBNA
1 
EBNA
2 
EBNA
3A 
EBNA
3B 
EBNA
3C 
EBNA
LP 
LMP
1 
LMP
2A 
LMP
2B 
EBERs Disease 
Type I + - - - - - - - - + Burkitt’s Lymphoma 
Type II + - - - - - + + + + 
Nasopharyngeal 
Carcinoma, 
Hodgkin’s Disease, 
Peripheral T-cell 
Lymphoma 
Type III + + + + + + + + + + 
Lymphoproliferative 
Disease, X-linked 
Lymphoproliferative 
Disease, 
Immunoblastic 
Lymphoma 
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Figure 2. The Epstein–Barr virus genome. a. Electron micrograph of the Epstein–Barr virus 
(EBV) virion. b. Diagram showing the location and transcription of the EBV latent genes on the 
double-stranded viral DNA episome. The orange segment represents the origin of replication 
(OriP). The large green solid arrows represent exons encoding each of the latent proteins, and the 
arrows indicate the direction in which the genes encoding these proteins are transcribed. The latent 
proteins include the six nuclear antigens (EBNA-1, 2, 3A, 3B and 3C, and EBNA-LP) and the three 
latent membrane proteins (LMP-1, 2A and 2B). EBNA-LP is transcribed from a variable number of 
repetitive exons. LMP-2A and LMP-2B are composed of multiple exons, located on either side of 
the terminal repeat (TR) region, which is formed during the circularization of the linear DNA to 
produce the viral episome. The blue arrows at the top represent the highly transcribed 
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nonpolyadenylated RNAs EBER-1 and EBER-2; their transcription is a consistent feature of latent 
EBV infection. The long outer green arrow represents EBV transcription during the latency III, in 
which all the EBNAs are transcribed from either the Cp or Wp promoter; the different EBNA are 
encoded by individual mRNA that are generated by differential splicing of the same long primary 
transcript. The inner, shorter red arrow represents the EBNA-1 transcript, which originates from the 
Qp promoter during Lat I and Lat II. c. Location of open reading frames for the EBV latent proteins 
on the BamHI restriction-endonuclease map of the prototype B95.8 genome (from Young LS et al, 
2004 modified). 
 
1.1.3 EBV type 1 and 2 
Two EBV types are recognized and usually known as 1 and 2, although A and B were widely used 
in the past. They were classified according to the differences on EBNA-2; EBV isolated from a 
North American case, B95-8, classified as type 1, was found to have a slightly longer EBNA-2 
reading frame than that of AG876, a type 2 virus isolated from a BL case in Central Africa. 
Additional differences between the genomes of type 1 and 2 appear in genes that encode for the 
EBNA-LP, 3A, 3B and 3C proteins. 
EBV type 1 is more common in most populations; 80% to 90% of EBV isolates from Caucasian and 
Southeast-Asian population are type 1. However these observations, largely based on in vitro virus 
isolation, still have to be fully verified by direct analyses ex vivo, thereby avoiding potential bias 
introduced by the more efficient in vitro transforming function of EBV type 1 strain (Rickinson and 
Kieff, 2007). EBV type 2 show an almost equal prevalence of EBV type 1 in the populations of 
Africa and New Guinea. EBV type 2 is also frequently detected among people infected with HIV-1 
(Rickinson and Kieff, 2004). Another question unsolved is whether particular EBV strains carry 
greater disease risk; to date, no clear evidence has been found of strain-specific disease association 
(Rickinson and Kieff, 2004). 
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1.1.4 EBV-associated lymphomas in HIV-1 infected individuals 
In healthy individuals, EBV infection is tightly controlled by both humoral and T cell-mediated 
immune responses. Immunodepression was long considered to play pivotal role in the etiology of 
cancer. Immunosurveillance was argued to be the central mechanism for checking tumour 
development and predictions were risen about immunosuppressed individuals being at increased 
risk of developing cancer (Beral V et al, 1998). Patients with HIV-1 infection present an high risk 
of developing EBV-related diseases, ranging from lymphoprolipherative disorders to B-cell non-
Hodgkin’s lymphomas (NHL), including BL, DLBCL, IBL and primary central nervous system 
lymphoma (PCNSL) (Carbone A et al, 2009). 
Besides immunodepression, chronic immune activation, a hallmark of HIV-1 pathogenesis 
(Douek DC et al, 2009), may play a critical role in the genesis of B-cell lymphomas (Grulich AE et 
al, 2002; Moir S et al, 2009). Polyclonal B-cell activation was one of the first described 
immunological abnormalities in HIV-1 infected individuals (Lane HC et al, 1983; Brenchley JM et 
al, 2006). Cell activation driven by HIV-1 antigens, and impaired immunosurveillance against EBV 
may result in chronic B-cell stimulation and expansion of EBV-infected B-cells (Gaidano G et al, 
1995; Righetti E et al, 2002; Burighel N et al, 2006), thus increasing the risk of developing EBV-
related malignancies. The factors that may contribute to HIV-1 induced B-cell activation and 
expansion of EBV-infected B-cells are largely unknown. Several cytokines and growth factors have 
been suggested to directly or indirectly trigger the activation of B cell in HIV-1 infected individuals. 
The expression of IL-2 receptor is greatly enhanced in B lymphocytes of HIV-1-infected subjects, 
and IL-2 may directly stimulate in vitro proliferation of B-cells (David D et al, 1998). Several 
cytokines, such as tumor necrosis factor (TNF)-α, IL-10 and IL-6, may stimulate proliferation and 
activation of B-cells (Macchia D et al, 1993; Mauray S et al, 2000). Furthermore, the bulk of CD4 
T-cell depletion induced by HIV-1 infection occurs rapidly within the first few week of infection 
and is predominantly localized to the gastrointestinal tract (Brenchley JM et al, 2006), causing an 
early breach in the integrity of the mucosal immune system. Notably, the extent of mucosal CD4 T-
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cell depletion in pathogenic Simian Immunodeficiency Virus (SIV) infection of Rhesus Macaques 
determine the rate of progression to AIDS (Picker LJ et al, 2004). This has led to the concept that 
injury to immune component of gastrointestinal mucosal surface, along with damage to the 
intestinal epithelial microenvironment with its antimicrobial functions, may affect systemic immune 
activation during the chronic phase of HIV-1 infection through the increase translocation of luminal 
microbial products (Brenchley JM et al, 2006), a phenomenon defined as microbial translocation. 
Damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs) translocate into circulation after HIV-1 induced cellular/tissue damage. DAMPs are 
endogenous molecules released by damaged, apoptotic, or secondary necrotic cells that trigger a 
potent innate immune response and cause inflammation through the engagement of the Toll-Like 
Receptor (TLRs) (Zhang Q et al, 2010; Cossarizza A et al, 2011). PAMPs are exogenous molecules, 
produced and released by several microorganisms, such as bacterial lipopolysaccharide (LPS) and 
16S ribosomal DNA (16S rDNA). LPS is a major component of Gram-negative bacterial cell walls 
and a potent immunostimulatory product; it can be quantitatively assessed in plasma and is directly 
associated with the degree of intestinal permeability following invasive gastrointestinal surgery 
(Brenchley JM et al, 2006). 16S rDNA is a DNA sequence encoding the well-conserved 16S rRNA 
subunit common to most bacteria (Jiang W et al, 2009). PAMPs trigger a potent innate immune 
response, activate several signalling pathways, through the engagement of several TLRs, in 
particular TLR-4 (Medzhitov R, 2001), induce production of pro-inflammatory cytokines and 
activate B-cells. 
The introduction of antiretroviral therapy (ART) into clinical practice has dramatically changed the 
development of HIV-1 related diseases. Deaths from AIDS-related diseases have been reduced by 
75% (Tirelli U et al, 2001) and people diagnosed with HIV-1 can expect to live for 30 or 40 years 
after infection, equivalent to about a one-third reduction in lifespan (Grulich AE, 2009). The use of 
protease inhibitor (PI) treatment alone or used with non-nucleoside-analogue reverse-transcriptase 
inhibitors (NNRTI) as part of combination drug regimens, has profoundly modified the natural 
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course of HIV-1 infection, resulting in a significant and sustained decrease in HIV-1 RNA 
plasmaviremia, an increase in CD4 T cells, and a decrease in HIV-1-associated opportunistic 
infections, thus indicating restoration of immune function (Palella FJ Jr et al, 1998). After ART 
introduction, the incidence of Kaposi’s Sarcoma (KS) is declining whereas the situation for EBV-
related malignancies seems to be less favourable (Simard EP et al, 2011). It can be advanced that 
improved immune function and reduced B cell stimulation in patients receiving ART may reduce 
the risk of developing lymphomas. However, it is possible that patients treated with ART may 
survive longer, with continued B cell stimulation resulting in an increased risk of lymphoma over 
time. Discordant response to ART with persisting HIV-1 plasma viremia and chronic immune 
activation may contribute to sustaining B-cell activation and increasing EBV levels.  
 
1.1.5 EBV in Africa 
The relationship between EBV, immunodeficiency and immune activation is of great interest also in 
African countries, where EBV seroprevalence is nearly universal, with acquisition in early 
childhood (Orem J et al, 2007). EBV-associated lymphomas represent an important cause of 
morbidity and mortality in children (Cader FZ et al, 2010). NHL commonly occurs in African 
children, with endemic BL being the most common subtype (Walusansa et al, 2012). The endemic 
form of BL was first described in 1958 in Africa by Denis Burkitt, who noted its high prevalence in 
young children and its geographic distribution around the equatorial belt of Africa, apparently 
determined by climate and other factors, such as holoendemic malarial infection, EBV and HIV-1.  
EBV plays a pivotal role in the pathogenesis of BL and in African countries, such as Uganda, the 
association of BL with EBV is very strong (Orem J et al, 2007). BL accounts for up to 75% of all 
childhood malignancies (Cader FZ et al, 2010), withs an annual incidence of 5 to 10 cases per 
100.000 and a peak incidence at 6/7 years of age (Magrath IT, 2006).  
Malaria represents an additional risk factor for endemic BL (Carpenter LM et al, 2008; Mutalima N 
et al, 2008). Malaria engages TLR-9 and induces the EBV latently infected memory B cells to 
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proliferate, thus leading the stimulation of EBV infected B cells and increasing the risk of 
emergence of a malignant B-cell clone (Rochford R et al, 2005).  
High levels of EBV-DNA represent a risk factor for the onset of EBV-related malignancies. To 
date, no data are available about EBV load and related malignancies in the context of HIV-1 
infection in African children. The absence of these data may be partly due to lack of access of 
equipped laboratories. One possible strategy to improve diagnosis is to simplify the collaboration 
between institutions in developed and developing countries, and/or between small laboratories and 
central facilities of the same country. Dried Blood Spot (DBS) may represent an easy method to 
collect and store blood samples and allow their reliable transport to specialized laboratories. DBS 
cards have successfully been used for metabolic disease screening in neonates (Guthrie et al, 1963). 
More recently, DBS filter papers are used to diagnose and monitor different DNA/RNA viral loads 
(Snijdewind IJ et al, 2012). However, to date no studies investigate the quantification of EBV-DNA 
levels from DBS. Therefore, DBS may represent an easy method to collect and store blood samples 
at remote sites where the laboratory equipment, personnel, or infrastructures may not be available.  
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Aims 
My PhD research focused on the following themes: 
1) the relationship between marker of immune activation and EBV load in HIV-1 infected patients; 
2) the EBV infection in HIV-1 infected and uninfected children in African countries.  
3) a new application of Dried Blood Spot to type and quantify EBV, and to identify B cell 
clonality in order to expand possibilities for diagnosis and monitoring of EBV-associated B cell 
malignancies.  
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 Abstract 
Background: Epstein-Barr Virus (EBV) is involved in a wide range of malignancies, particularly in 
immunocompromised subjects. Besides immunodepression, chronic immune activation may induce 
B-cell stimulation leading to an expansion of EBV-infected cells,  thus increasing the risk of EBV-
related malignancies. In Africa, EBV primary infection occurs during early childhood, but little is 
known about EBV load in HIV-1-infected children.  
Methods: Dried Blood Spot (DBS) samples from 213 HIV-1-infected children (0-18 years), 140 of 
whom were on antiretroviral therapy (ART), were collected at Nsambya Home Care. DNA was 
extracted and tested to quantify both EBV type 1 and EBV type 2 by multiplex real-time PCR. A 
real-time PCR assay was set up to quantify 16S ribosomial DNA (16S rDNA). Statistical analyses 
were performed using STATA software.  
Results: 92 of 140 (66%) children on ART and 57 of 73 (78%) ART-naive children were found to 
be EBV-positive. EBV type 1 and EBV type 2 were detected in 31 (22%) and 21 (15%) children on 
ART, and in 15 (21%) and 11 (15%) ART-naive children, respectively; 40 (29%) children on ART 
and 31 (42%) ART-naive children were co-infected with both EBV types. After adjusting for CD4Z 
score, age and WHO stage, children on ART had less odds of having detectable EBV (OR 0.39 
[95% CI 0.16-0.94], p=0.036). Mean [interquartile-IQR] levels of EBV-DNA were similar in 
children positive for EBV type 1 (3.80 [3.45-3.88] log10 copies/ml) or EBV type 2 (3.92 [3.52-4.29] 
log10 copies/ml), but higher in children co-infected with both viruses (4.34 [3.95-4.61] log10 
copies/ml; overall p=0.001). EBV load was significantly higher in ART-naive children than those on 
ART (4.22 [3.87-4.58] vs 3.99 [3.55-4.33] log10 copies/ml; p= 0.016). Levels of 16S rDNA were 
significantly higher in ART-naive children than those on ART (2.16 [2.11-2.28] vs 2.09 [2.02-2.22] 
log10 copies/µl; p=0.007) and correlated with EBV-DNA levels (r= 0.382, p=0.016).  
Conclusions: These finding suggest that chronic immune activation, induced by HIV-1 and 
circulating microbial products, leads to an increase of  EBV load,  a risk factor for the development 
of EBV-related malignancies. Treatment with ART, likely by limiting immune activation, may  
prevent  B cell activation and  expansion of EBV-infected B cells.  
 1. Introduction 
Epstein-Barr Virus (EBV) is a gammaherpes virus involved in a wide range of malignancies, 
particularly in immunocompromised subjects, ranging from lymphoproliferatives disorders to B cell 
non-Hodgkin's lymphomas (NHL) (1,2). 
 Besides immunodepression, chronic immune activation, a hallmark of HIV-1 pathogenesis 
(3), may play a critical role in the genesis of B cell lymphomas (4,5). Cell activation driven by HIV-
1 antigens, together with impaired immunosurveillance against EBV, may result in chronic B cell 
stimulation and expansion of EBV-infected B cells (6-8), thus increasing the risk of developing 
EBV-related malignancies. The factors that may contribute to HIV-1-induced B cell activation and 
expansion of EBV-infected cells are largely unknown. Massive HIV-1-induced T cell depletion 
causes a damage to intestinal mucosa, thus promoting a translocation of pathogen-associated 
molecular patterns (PAMPs) into circulation. PAMPs are exogenous molecules, produced and 
released by several microorganisms, such as 16S ribosomal DNA (16S rDNA). PAMPs trigger a 
potent innate immune response, causing immune activation through the engagement of several Toll-
like receptors (TLRs), and may also activate B cells (9).  
Antiretroviral therapy (ART) has greatly modified the natural course of HIV-1 infection, 
resulting in decreased HIV-1 load, increased CD4 T cells, and decreased HIV-1-associated 
opportunistic infections, thus indicating restoration of immune function (10). While the incidence of 
HIV-1 related malignancies, such as Kaposi sarcoma (KS), has declined markedly as access to ART 
has expanded throughout Europe and North America, the incidence of NHL still remains elevated 
(11). The trend of incidence of NHL in HIV-1 infected African patients has not been estimated (12). 
In Africa, EBV primary infection occurs during infancy and early childhood, and EBV-
associated lymphomas represent an important cause of morbidity and mortality in children. NHL 
commonly occur in African children, with endemic Burkitt’s Lymphoma (BL) being the most 
common subtype (13). Endemic BL is strongly associated with EBV and accounts for up to 75% of 
all childhood malignancies (14). BL, in  the central part of Africa, counts an annual incidence of 5 
 to 10 cases per 100 000, and a peak incidence at 6/7 years of age (15). Malaria may represent an 
additional risk factor for BL (16,17); malaria induce B cell activation, thus leading to the 
stimulation of EBV-latent infected B cells (18).  
High levels of EBV are a risk factor for the onset of EBV-related malignancies. To date, no 
data are available about EBV-infection and related malignancies in the context of HIV-1 infection in 
African children. The absence of these data may be partly due to the lack of access of laboratory 
analyses in developing countries. One possible strategy to improve diagnosis is to simplify the 
collaboration between institutions in developed and developing countries, and/or between small 
laboratories and central facilities of the same country. Dried Blood Spot (DBS) may represent an 
easy method to collect and store blood samples and allow their reliable transport to specialized 
laboratories.  
 
 
2. Material and Methods  
2.1 Patients and sample collection 
This is a cross-sectional study, conducted in the Home-Based Care department of the St. Raphael of 
St. Francis Hospital at Nsambya in Kampala, Uganda. Blood samples from 213 HIV-1-infected 
children (0-18 years) were collected. At the time of sampling for this study, 140 (66%) children 
were on ART and 73 (34%) were under no therapy (ART-naive).  
Blood from each child was collected in EDTA-containing tubes by trained nurses. 50 µl of this 
blood-EDTA were spotted onto each circle of Protein Saver TM 903 Card (Whatman GmbH, 
Hahnestra, Germany) and 5 blood spots were prepared for each card with one blood sample. DBS 
were dried at room temperature overnight, stored in individual ziplock bags containing a desiccant, 
and sent to the laboratory of the Department of Surgery, Oncology and Gastroenterology, Section of 
Oncology and Immunology, University of Padova, Viral  Oncology Unit and AIDS Reference 
Centre, Italy. This study was approved by the Ethical Committee of the Uganda. 
 
 2.2 DNA elution 
From each 50 µl DBS, three 3 mm-diameter circles, equivalent to 5 µl of whole blood each (15 µl 
total), were used to extract DNA with the Qiagen DNA MicroKit (Qiagen, Hilden, Germany) and 
were resuspended in a final volume of 50 µl. To control the ability of eluted DNA to be amplified, 5 
µl of final elution were amplified for the human telomerase reverse transcriptase (hTERT) located in 
the 5p15.33 (Gen Bank accession: AF128893), and employed as housekeeping gene. Amplification 
was carried out as previously described (19).  
 
2.3 EBV-DNA quantification.  
A quantitative method, based on Multiplex Real-Time PCR assay, was performed to quantify EBV 
type 1 and EBV type 2, exactly as described (20). A standard reference curve was obtained by five-
fold serial dilution of two amplicons, one for EBV type 1 and the other for EBV type 2, and 
amplification was performed, as already detailed (20). The multiplex assay showed a dynamic range 
from 2 to 2x105 copies. The results were expressed as EBV-DNA copies/ml.  
 
2.4 16S rDNA quantification  
A quantitative method based on a Real-Time PCR assay was performed to quantify 16S rDNA, 
using primer pair and probe as described (21). A standard curve was generated from five-fold serial 
dilution of plasmid DNA containing known copy numbers of the template. The assay showed a 
dynamic range from 3 to 2.5x105 copies. Results were expressed as 16S rDNA copies/µl. 
 
2.5 Definition of clinical malaria  
Clinical malaria was defined by clinicians as a state in which a child presents symptoms that are 
suggestive of malaria. The symptoms range from mild headaches, high or mild fever, fatigue and 
joint pains in mild cases to malaise, marked weakness, loss of appetite, chills and rigors, nausea, 
vomiting, diarrhoea, convulsions, lethargy or drowsiness, and dark urine from hemolysis. 
 2.6 Statistical analyses 
Firstly, missing data and small subject numbers in sub-groups were identified, the distribution for 
all variables was established and EBV data were log10 transformed. EBV outcomes were cross-
tabulated against all interesting variables to strengthen the understanding of their potential for 
confounding or interaction. Odds ratios (OR) were calculated for each with 95% confidence 
intervals (CI) and chi-square p-values.  
Logistical regression analysis was undertaken to allow the adjustment of multiple confounders. 
Considering a model containing main exposure, outcome of interest and all potential and apriori 
confounders, an iterative Likelihood Ratio Tests (LRTs) was conducted using alternative models 
which removed these potential confounders according to perceived ’strength’ or importance. The fit 
of the model was assessed by the magnitude of the observed change in OR supported by the 
outcome of LRTs.  
Analyses were also performed looking at the mean difference in the quantitative levels of EBV; 
univariate analysis was undertaken using t-tests to compare the log10 mean viral loads. 
 
3. Results 
3.1 EBV-DNA levels in HIV-1 infected children  
The baseline characteristics at time of sample collection of the entire cohort of HIV-1 infected 
children enrolled were described in Table 1. Of the total 213 HIV-1-infected children, 149 (70%) 
children were found to have EBV detectable, 92 out of 140 (66%) on ART and 57 out of 73 (78%) 
ART-naive. EBV type 1 and EBV type 2 were detected in 31 (22%) and 21 (15%) children on ART, 
and in 15 (21%) and 11 (15%) ART-naive children, respectively. Co-infection with both EBV types 
was observed in 40 (29%) children on ART and 31 (42%) ART-naive children (Figure 1).  
Univariate analysis identified differences in EBV-DNA detection between ART and ART-naive 
children (OR= 0.41 [95% CI: 0.45-1.05] p= 0.0793). This tendency was supported by a multivariate 
model. Indeed, after adjusting for CD4-Z score, age and WHO stage, children on ART presented  
 less odds of EBV-DNA detection in peripheral blood than ART-naïve children (OR= 0.39 [95% CI 
0.16-0.94], p= 0.036) (Table 2).  
Mean [interquartile-IQR] levels of EBV-DNA were similar in children infected with EBV type 1 
(3.80 [3.45-3.88] log10 copies/ml) or EBV type 2 (3.92 [3.52-4.29] log10 copies/ml), but higher in 
children co-infected with both viruses (4.34 [3.95-4.61] log10 copies/ml; overall, p= 0.001) (Figure 
2A). Overall, EBV load was significantly higher in children ART-naive than in those on ART (4.22 
[3.87-4.58] vs 3.99 [3.55-4.33] log10 copies/ml; p= 0.016) (Figure 2B).  
 
3.2 EBV-DNA levels in relation to markers of immune activation 
Levels of 16S rDNA were significantly higher in children ART-naive compared to those on ART 
(2.16 [2.11-2.28] vs 2.09 [2.02-2.22] log10 copies/µl; p=0.007) (Figure 3A). Furthermore, EBV-
DNA levels significantly correlated with levels of 16S rDNA in ART-naive children (rp= 0.382; p= 
0.016) (Figure 3B).  
B cell activation may also be driven by malaria (Rochford et al 2005); thus, EBV-DNA load was 
evaluated in children with or without clinical malaria. Percentages of infection with EBV type 1, 
type 2 or co-infection reached 30%, 4%, and 44% respectively, in children with clinical malaria; 
28%, 17%, and 29% respectively, in children without clinical malaria. Levels of EBV-DNA tended 
to be higher in children with clinical malaria (3.82 [3.45-4.33] vs 3.37 [2.00-4.17] log10 copies/ml; 
p= 0.093) (Figure 4). 
 
Discussion 
 DBS filter papers are already commonly used for the diagnosis and monitoring of different 
DNA/RNA viral loads (22). However, to date very few studies (23) investigate the quantification of 
EBV-DNA levels from DBS. Previously, EBV antibodies (IgA and IgG) were tested successfully in 
eluates from DBS cards to define EBV serostatus in neuroimmunology studies (24) and in 
 nasopharyngeal carcinoma screening (25). While serological tests confirm primary infection and 
document remote infection, quantitative EBV-DNA assessments are increasingly emerging as an 
important laboratory tool in supporting the diagnosis and monitoring of EBV-associated diseases 
(19). In some regions of Africa, such as Uganda, EBV seroprevalence is nearly universal, with 
acquisition in early childhood, and there is a striking association of EBV with BL (26). Therefore, 
EBV viral load assessment in peripheral blood compartments may represent an important 
instrument in clinical practice for the prevention, diagnosis and monitoring of EBV-associated 
lymphoproliferative diseases, even more in African children whereas EBV-associated lymphomas 
are an important cause of mortality and morbidity. DBS sampling allows us to extend EBV load 
assays not only to cases from the developing world, but it also gives us the opportunity to collect 
specimens from young children in whom venipuncture is difficult to perform. Our results show that 
it is possible to perform EBV-DNA and, for the first time, 16S rDNA load assessment on DBS 
sampling, thereby improving the diagnostic and monitoring capabilities in resource-limited settings. 
 Chronic immune activation, a hallmark of HIV-1 infection, may contribute to the expansion 
of EBV-infected B cells. One of the mechanisms by which HIV-1 activates B cells probably 
involves PAMPs. They are released into circulation after HIV-1-induced cellular/tissue damage, 
they engage TLRs and induce a potent immune response, involving B cells. In this study we found 
that EBV-DNA and 16S rDNA levels were significantly lower in children on ART than in those 
ART-naive, suggesting that treatment with ART lowered microbial translocation. Furthermore, 
malaria may induce B cell activation, leading to the stimulation of EBV-infected B cells via TLR-9 
engagement (18). In this study, we found that 16S rDNA levels significantly correlate with levels of 
EBV-DNA in ART-naive children, and EBV-DNA levels tend to be higher in children with clinical 
malaria. These findings indicate that chronic immune activation induced by HIV-1, circulating 
microbial products and co-infections, such as malaria, may lead to the expansion of EBV-infected B 
cells, thus increasing EBV load. Findings that children on ART had lower EBV-DNA levels than 
 ART-naive children, suggest that treatment with ART may prevent B cell stimulation and expansion 
of EBV-infected B cells. 
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 Table 1: Baseline descriptive characteristics of HIV-1 infected children 
Characteristic n° children (%) 
On ART (n=213) No 73 (34) 
Yes 140 (66) 
WHO Stage (n=209) I 60 (29) 
II 120 (57) 
>= III 29 (14) 
WHO Stage of children on ART (n=140) I 23 (16) 
II 97 (70) 
>= III 20 (14) 
ART Type (n=140) NVP Based 97 (69) 
EFV Based 34 (24) 
LPV Based 8 (6) 
3-NRTI 1 (1) 
CD4 Category (n=177) <350 18 (10) 
350-750 68 (38) 
750-1000 41 (23) 
>1000 50 (29) 
 
All characteristics refer to the time of sample collection 
 
Table 2. Multivariate models and adjusted odds ratios of EBV detection among HIV-1 infected 
children on ART vs ART-naive  
Outcome Exposure Covariates Adjusted OR 95% CI p-value 
EBV Total ART CD4 Z-Score; Age; WHO Stage 0.39   0.16-0.94 0.036     
EBV1 ART CD4 Z-Score; Age; WHO Stage 0.56  0.28-1.14 0.111     
EBV2 ART CD4 Z-Score; Age; WHO Stage 0.51   0.24-1.11 0.090     
EBV co-infection ART CD4 Z-Score; Age; WHO Stage 0.45  0.20-1.00 0.050     
 
 
 
 
 
 
 
 
 Legend to figure 
 
Figure 1. EBV infection in HIV-1 infected children. Percentage of detectable EBV-infection in all 
HIV-1 infected children and in children sub-grouped according to therapy: on ART or ART-naive. 
 
Figure 2. EBV-DNA load in HIV-1 infected children. EBV-DNA levels in HIV-1-infected 
children A) sub-grouped according to infection with EBV type 1, EBV type 2 or co-infection with 
both EBV types; B) sub-grouped according to therapy: on ART or ART-naive. Each plot represents 
a child. The lines indicate the mean values.  
 
Figure 3. 16S rDNA levels in HIV-1-infected children. 16S rDNA levels in HIV-1-infected 
children A) sub-grouped according to therapy: on ART or ART-naive; B) correlation with EBV-
DNA levels in ART-naive children. Each plot represents a child. 
 
Figure 4. EBV-DNA load and clinical malaria. EBV-DNA levels in HIV-1-infected children with 
or without clinical malaria. Each plot represents a child. The lines indicate the mean values. White 
dots represent patients on ART, black dots represent ART-naive patients.  
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CHAPTER 5 
 
Dried Blood Spot (DBS) Sampling for Detection of Monoclonal IGH Gene 
Rearrangement and EBV Load: a Tool for Improving the Diagnosis of 
Lymphoproliferative Diseases in Resource-Limited Settings 
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 Abstract 
In many lymphoproliferative disorders complementary molecular methods are required in order to 
provide a conclusive diagnosis. The reliability of lymphoma diagnosis is strikingly different 
between developed and developing countries, partly due to lack of access to advanced molecular 
analyses. To overcome these hurdles, a new application of dried blood spots (DBS) is proposed for 
detecting clonal B-cell populations in peripheral blood (PB), and for the quantification of Epstein 
Barr Virus (EBV)-DNA levels.  
We first ensured that DBS contain sufficient lymphocytes to perform a clonality assay without 
yielding false positive results. Using Namalwa cells, we found a good relationship between the 
expected and detected EBV-DNA copies (r=0.987, p< 0.0001) and we established that a clonal B-
cell population on DBS was detected when there were at least 200 clonal cells in the analysed 
sample. EBV-DNA was detected even in the sample corresponding to 10 Namalwa cells. Moreover, 
very similar clonal results were obtained between DNA from DBS and fresh whole blood from 
patients with B-cell chronic lymphocytic leukemia (B-CLL). 
This is the first study demonstrating that it is possible to perform clonality testing and EBV load 
assessment on DBS sampling, thus improving the diagnostic and monitoring options for 
lymphoproliferative diseases in resource-limited settings.  
 
Keywords: Dried blood; clonality; IGH rearrangement; EBV; lymphoproliferative disease 
 
 Introduction 
In many lymphoproliferative disorders, despite well-established histomorphological and 
immunophenotypical criteria, complementary molecular methods are required to provide a 
conclusive diagnosis. Unfortunately, striking differences still exist in the reliability of lymphoma 
diagnosis between developed and developing countries, partly due to lack of access to these 
advanced molecular analyses. This is especially true in many African countries where lymphoma 
diagnosis is based on morphology alone and does not include most of the entities recognized in 
recent years. One possible strategy to improve diagnoses is to simplify the collaboration between 
institutions in developed and developing countries, and/or between small laboratories and central 
facilities of the same country. According to published data, in about 10% of patients with suspected 
lymphoproliferative disorders, PCR-based clonality testing can be useful in discriminating between 
a reactive lymphoproliferation with polyclonally rearranged immunoglobulin or T-cell receptor 
genes, and a malignant proliferation with clonal rearrangements.1-3 Although lymph nodes and bone 
marrow (BM) are the tissues of choice for the detection of monoclonal population in leukaemias 
and lymphomas, peripheral blood (PB) has been shown to be a reliable and safe tissue for detecting 
malignant clones.4 The demonstrated concordance of clonality testing between BM and PB samples 
supports the use of PB samples for a non-invasive detection and monitoring of clonality in the 
management of patients with lymphoproliferative disorders.  
 Clonality analysis in PB requires fresh whole blood and reliable transport to laboratories 
with specialized equipment. As such, an easy blood collection and conservation method could 
improve diagnosis in most cases. One option relies on the use of filter paper for blood collection; its 
analysis was implemented as early as the 1960s by Guthrie et al. using dried blood spot (DBS) for 
newborn phenylketonuria detection.5 DBS on “Guthrie card” filter paper is widely used in many 
types of tests, including chemical, serological, and genetic applications.6-8 These filter papers are 
made from high-purity cotton linters, manufactured to give accurate and reproducible absorption of 
blood specimens according to Clinical and Laboratory Standards Institute (CLSI) specifications.9 
 The simple puncturing of the skin for blood collection onto paper has become an important tool in 
screening individuals for clinical purposes and epidemiological studies. DBS ensures easy sample 
handling, transport, and storage, especially for samples collected at remote sites where the 
laboratory equipment, personnel, or infrastructures necessary for the correct handling of blood 
samples may not be available. Viral RNA and DNA, antibodies or other proteins and antiviral drugs 
or their metabolites remain stable in DBS cards for relatively long periods when stored with 
desiccant in closed bags at ambient temperature, as compared with wet plasma or serum stored 
under the same conditions.8, 10 
 Here we present a new application of DBS for the detection of clonal B-cell populations in 
PB for the diagnosis and monitoring of B-cell malignancies. DBS sampling still faces technical 
limits that need attention, especially for diagnostic analyses. The small quantity of spotted blood (50 
µl) might have been a major limitation for the use of the DBS in the detection of clonal lymphocytic 
populations. We hypothesized that by using serial dilutions of a clonal B-cell line in fresh blood, it 
might be possible to define a sensitivity cut-off for the clonality assay, i.e. the lowest number of 
malignant cells reliably detectable as a cellular clone.  
 We also used DBS to detect Epstein-Barr Virus (EBV) viral load. EBV infects B 
lymphocytes, has a potent transforming ability, and has been implicated in the development of a 
wide range of B-cell malignancies, including Burkitt’s lymphoma (BL), Hodgkin disease (HD), and 
lymphomas arising in immunocompromised individuals, i.e. post-transplant lymphoproliferative 
diseases (PTLD) and Human Immunodeficiency Virus (HIV)-associated lymphoproliferative 
disorders.11, 12 In Africa, primary infection with EBV occurs during infancy and early childhood; 
EBV-associated lymphomas are an important cause of mortality and morbidity in children, and BL 
in African children account for up to 75% of all childhood malignancies.13 
 Our results demonstrated that the use of DBS sampling is a feasible tool for the molecular 
analysis of PB in leukaemia/lymphoma or virus-infected (i.e. EBV) patients. Its application could 
 therefore be extended to the diagnosis and monitoring of lymphoproliferative disorders, particularly 
in resource-limited settings.  
 
Materials and Methods 
Blood, cell line and DBS samples. 
Blood was taken from five consenting healthy volunteer donors at the Instituto Oncologico Veneto, 
IOV-IRCCS, of Padova, Italy. Six B-cell chronic lymphocytic leukemia (B-CLL) samples were 
referred to the diagnostic laboratory at the IOV-IRCCS for routine clonality testing to complete the 
pathologist’s diagnosis of B-CLL. All venous blood samples were collected in EDTA vacutainer 
tubes and parallel samples were prepared: 50 µl of blood were spotted on Protein Saver TM 903 
Card (Whatman GmbH, Hahnestra, Germany) dried overnight at room temperature, and 500 µl of 
whole blood were transferred to Eppendorf tube for DNA extraction.  
 The Namalwa cell line, an EBV-positive BL cell line that is known to carry two integrated 
EBV type 1 genomes per cell,14 was established at the initial concentration of 106 cells/ml and 
diluted into whole blood from healthy donors to obtain 200-150-100-50-40-20-2-0 Namalwa cells 
per µl of blood. Fifty µl of each dilution were spotted on filter paper card. All DBS samples were 
prepared in duplicate. A pellet with only Namalwa cells was used as a positive control of 
monoclonality. 
 
DNA extraction  
Genomic DNA was isolated using the automated MagNA Pure Compact instrument (Roche 
Applied Science, Indianapolis, IN). Briefly, 500 µl of fresh blood were processed according to the 
manufacturer's protocol included in the MagNA Pure Compact Nucleic Acid Isolation kit I-Large 
Volume (Roche Applied Science), with the elution volume set at 200 µl. For DNA extraction from 
DBS cards, one spot with 50 µl of dried blood was added to a 1.5-ml Eppendorf tube, and manually 
cut into pieces, avoiding cross-contamination. External lysis step was performed in 180 µl of 
 MagNA Pure DNA Tissue Lysis Buffer (Roche Applied Science) and 20 µl of proteinase K 
solutions, at 56°C overnight. After inactivation of proteinase K at 90°C for 10 minutes, and 
adjustment of final volume to 500 µl with additional phosphate buffered saline (PBS), the DNA was 
extracted using the automated MagNA Pure Compact Nucleic Acid Isolation kit (Roche Applied 
Science) protocol with the elution volume set at 50 µl, which is the minimum elution volume 
permitted by the protocol. The concentration of DNA extracted was determined using a 
spectrophotometer (NanoDrop ND-1000, Wilmington, Delaware, USA). We recovered 
approximately 11-24 ng/µl of DNA from DBS cards. 
 
Clonality assay 
The extracted DNA samples were tested for B-cell immunoglobulin heavy chain (IGH) clonality 
using the IGH Gene Clonality Assay (Invivoscribe Technologies, San Diego, CA), containing 
BIOMED-2 primers, in accordance with the manufacture's protocol. As with specimens with 
limited DNA the recommended multiplex PCRs for suspected B-cell proliferations are the three 
framework subregion (FR) of the IGH gene, preferably followed by the immunoglobulin kappa 
(IGK) targets,15 we used the IGH FR1, FR2 and FR3 Master Mix, as well as the Specimen Control 
Size Ladder Master Mix for template amplification control. Each PCR reaction was prepared using 
the maximum volume of DNA provided in the protocol (5 µl) for DBS cards or 50 ng of DNA 
extracted directly from fresh blood. These post-PCR products were visualized by means of capillary 
electrophoresis on the ABI PRISM 3730XL Genetic Analyzer with subsequent software analysis 
using ABI GeneMapper 4.0 analysis software (Applied Biosystems). All samples were tested twice. 
A sample was considered clonal only if one or two reproducible peaks were detected within the 
valid range. Known nonspecific peaks were excluded to avoid false positives.1 
 
 
 
 EBV-DNA quantification 
EBV-DNA levels were quantified by qPCR, exactly as previously described, using the standard 
curve and the probe for the quantification of EBV type 1.16 The assay had a dynamic range from 5 
to 2x105 EBV-DNA copies.16 
 
Results 
Evaluation of polyclonal B cells on DBS. 
One of the limitations that can occur using DBS for laboratory diagnosis is the small quantity of 
sample, especially in analysing different cellular populations present in the blood. Since a single 
cell DNA can be amplify generating a single (clonal) amplification product, if there are very few 
normal lymphocytes in the test sample and a PCR-protocol for rearranged immunogenic gene is 
used to detect the presence of polyclonal cell populations, a false positive result may occur. To rule 
out this problem, despite the fact that the BIOMED-2 protocol establishes the use of at least 100 ng 
of DNA in each PCR reaction, we first verified if 50 ng of DNA from normal whole blood 
(corresponding to about 7500 cells) were sufficient to detect a normal polyclonal pattern 
corresponding to B-lymphocytes carrying the different immunoglobulin gene rearrangements. DNA 
was extracted from 500 µl of whole blood taken from five donors and 50 ng of each sample were 
analysed for FR1-JH, FR2-JH, FR3-JH rearrangements of the IGH gene; a polyclonal pattern was 
observed in all cases. From these same donors, 50 µl of blood were spotted on DBS filter and 5 µl 
(about 50 ng) of the 50 µl DNA extracted were analysed; polyclonal results were concordant with 
those obtained with DNA from fresh blood (Figure 1). Thus, 5 µl of spotted blood contain sufficient 
lymphocytes to perform an IGH clonality assay without false positive results.  
 
Lower Limit for Detecting Monoclonal IgH Gene Rearrangement on DBS. 
We assessed the lower limit of clonal detection in the PCR-based analysis of DBS samples using 
Namalwa B cells, diluted in whole blood of a healthy donor; 50 µl of each dilution were spotted on 
 DBS filters in duplicate. DNA extracted from each spot was resuspended in 50 µl of water, and 5 µl 
(corresponding to 5 µl of blood) were employed in each reaction for FR1-JH, FR2-JH, FR3-JH 
rearrangements, applying the BIOMED-2 protocol. DNA from 100% Namalwa cells (N) revealed a 
monoclonal IGH gene rearrangement within all three framework regions. With DNA from 
Namalwa diluted in normal blood, the highest sensitive clonal signal was obtained with primers 
amplifying sequences between the FR2-JH and FR3-JH regions. As reported in Figure 2, a positive 
clonal signal could be detected in DBS samples containing 40 Namalwa cells per µl of blood. DBS 
samples with 20 or 2 Namalwa cells/µl revealed only a polyclonal pattern, similar to DBS spotted 
only with normal PB. Thus, clonal B-cell population on DBS can be detected by PCR-based 
methods when represented by at least 200 clonal cells in the sample.  
 
Evaluation of EBV-DNA on DBS 
Considering that Namalwa cells contain two integrated EBV genomes/cell,14 the number of 
Namalwa B clonal cells contained in samples diluted from DBS and analysed for clonality, was also 
verified by testing them for EBV-DNA. The number of EBV copies was estimated by qPCR and the 
values were compared to those expected. A very good relationship was found between the detected 
and expected EBV-DNA copy numbers (Figure 3). Of note EBV-DNA was also found in the DNA 
sample with 10 Namalwa cells (2 Namalwa cells/µl of whole blood, corresponding to 20 EBV/5µl), 
indicating that viral DNA was quantified in DBS samples using qPCR methods with a higher 
sensitivity than analysis of clonality, likely because of the absence of background.  
 
Clonality analysis on DBS from B-CLL. 
Lastly, we proved the reliability of our approach for clonality detection on DBS from patients with 
B-CLL. Equal amounts of DNA either extracted from DBS or from fresh blood samples taken from 
6 B-CLL patients were analysed using the same PCR-based approach. As reported in Figure 4, very 
 similar profiles, with similar migration distances and heights of clonal peaks, were present in both 
DBS and fresh blood samples from each patient. 
 
Discussion 
The use of DBS cards has been seen as a feasible tool for the diagnosis and monitoring of different 
diseases in the developing world. Initially they were used for metabolic disease screening in 
neonates,5 but with the development of new techniques, the disease range and applications of DBS 
have expanded significantly. Today, DBS cards are used to measure and analyse nucleic acids, 
proteins and small molecules overcoming the limitations of small sample sizes.6, 7 In this regard, we 
assessed if DBS sampling was also suitable to identify the presence of a B-cell clonal population 
circulating in the blood by immunoglobulin gene rearrangement analysis, with a view to offering a 
molecular valuation in the diagnosis and monitoring of lymphoproliferative diseases in resource-
limited settings. Difficulties in making a final diagnosis of lymphoid malignancies arise in a 
proportion of cases (5-10%), even with extensive histomorphology or immunophenotyping, and 
additional diagnostics, such as molecular clonality, are needed to generate or confirm the final 
diagnosis.  
 The first issue to consider is whether or not the DBS contains a sufficient number of B 
lymphocytes to detect normal polyclonal B-cell populations by PCR-analysis. This is an important 
aspect to consider in order to avoid possible false positive results (pseudoclonality) due to the 
amplification of the few immunoglobulin gene rearrangements derived from a limited number of B-
cells in the sample analysed. We applied the BIOMED-2 protocol for the analysis of B-cell 
clonality using PCR for three FR of the IGH. Thus, the DNA extracted from DBS had to suffice to 
perform at least the three PCR reactions specific for FR-IGH regions and the PCR-control for 
sample amplificability. Although the BIOMED-2 guidelines for the clonality assay suggest using at 
least 100 ng DNA, our experiments showed that about 50 ng of the DNA extracted corresponding to 
the DNA yielded from 5 µl of the spotted blood (corresponding to approximately 750-3600 B cells) 
 appeared to suffice to obtain the expected polyclonal pattern in each specific PCR reaction, as well 
as when normal fresh blood is analysed. Notably, while a previous study reported that 20 ng of 
DNA from normal tonsil, corresponding to 6000-9500 B cells, is required to detect a complete 
polyclonal pattern,17 we have shown that by using the multiplex PCR method and fluorescent 
analysis, less than half this number of B-cells is sufficient. 
 The second issue to evaluate is the sensitivity of the DBS approach in detecting the presence 
of a clonal cell population circulating in the blood. Since limited sensitivity may hamper the 
detection of small clonal cell populations, we determined how many B clonal cells (Namalwa) must 
be present in the blood for detection using DNA corresponding to 5 µl of spotted blood. We 
demonstrated that it is possible to identify the monoclonal pattern even in the sample with 200 
clonal Namalwa cells. Since a normal adult lymphocyte count is usually between 1000 and 4800 
lymphocytes/µl of blood, of which approximately 15% are B cells (about 400 B polyclonal 
lymphocytes/µl of blood),18 the detection of 40 clonal B-cells per µl of blood corresponds to a 
sensitivity of 10% using BIOMED-2 PCR protocol with DBS cards. Since the detection limit 
depends not only on the technique applied, but also on the relative size of the 'background' of 
normal (polyclonal) B-lymphocytes, it comes as no surprise that sensitivity is lower using DBS 
cards than fresh blood samples, in which the BIOMED-2 assay can reliably detect even 1-5 positive 
cell per 100 normal lymphocytes (1-5% of sensitivity).1 Moreover, taking advantage of the presence 
of two EBV copies per Namalwa cell,14 we investigated the size of the clonal Namalwa cells 
present in the DBS dilutions by means of qPCR for EBV-DNA. We found a good correlation 
between the expected and detected EBV copies and thus cell numbers. In addition, we detected 
EBV-DNA even in the sample containing 10 Namalwa cells (2 cells per µl of spotted blood, 
corresponding to 20 EBV copies in 5 µl). While DBS cards are already commonly used for the 
diagnosis and monitoring of different DNA/RNA viral loads,8 no studies are available regarding 
EBV-DNA levels. Previously, EBV IgG antibodies were tested successfully in eluates of DBS cards 
to define EBV serostatus in neuroimmunology studies19 and in nasopharyngeal carcinoma 
 screening.20 While serological tests confirm primary infection and document remote infection, 
quantitative EBV-DNA assessments are increasingly emerging as an important laboratory tool in 
supporting the diagnosis and management of EBV-associated disease.21, 22 Measuring EBV-DNA 
levels is an important tool for identifying patients at risk of PTLD and is a parameter for monitoring 
immunosuppressive therapy and initiating pre-emptive or antitumor therapy.23, 24 In some regions of 
Africa, such as Uganda, EBV seroprevalence is nearly universal, with acquisition in early 
childhood, and there is a striking association of EBV with BL.25 EBV viral load assessment is 
generally used in PB compartments in clinical practice for the prevention, diagnosis and monitoring 
of EBV-associated lymphoproliferative diseases, even more in African children whereas EBV-
associated lymphomas are an important cause of mortality and morbidity. DBS sampling allows us 
to extend EBV load assays not only to cases from the developing world, but also for giving the 
opportunity of collecting specimens from young children in whom venipuncture is difficult to 
perform.  
 Finally, we compared the use of DBS cards with fresh blood samples to perform clonality 
assay in B-CLL. In all samples analysed, we found the same clonal profile using DNA from both 
DBS cards and fresh blood. A clinical diagnosis of B-CLL is defined by absolute lymphocytosis of 
at least 5000/µl cells with an appropriate immunophenotype,26 thus DBS sampling can be a suitable 
collection system for identifying the clonal population circulating in the blood. A diagnosis of 
leukaemia is not usually problematic: immnophenotyping and cytogenetic analysis and the use of 
histochemical stains can establish the diagnosis in virtually all leukaemia cases. However, in some 
patients diagnosis is more complicated, or molecular analyses complementary to the 
histomorphological evaluation are not always available, hence a clonality assay using DBS cards 
might prove to be a valuable tool. Our results show that it is possible to perform clonality testing 
and EBV load assessment on DBS sampling, thereby improving the diagnostic and monitoring 
capabilities of lymphoproliferative diseases in resource-limited settings. 
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 Figure legends 
 
Figure 1. IGH gene polyclonality analysis. (A) IGH FR1-JH, (B) FR2-JH and (C) FR3-JH 
multiplex PCR GeneScan analysis using the polyclonal control (upper panels) and 50 ng of DNA 
extracted from DBS (middle panels) and fresh blood (lower panels) samples from one 
representative healthy donor, showing the typical polyclonal Gaussian patterns. 
 
Figure 2. Minimal detection of B-cell clonality. Namalwa B-cells (N) were serially diluted in 
normal blood (panels with 200, 150, 100, 50, 40, 20, 2 N/µl of blood). DBS cards were prepared 
using 50 µl of each dilution, and 5 µl of the 50 µl DNA extracted were analysed by multiplex PCR 
for IGH gene rearrangements. From a representative case, GeneScanning revealed that a distinct 
monoclonal peak with the expected position of 100% N, could still be detected at a dilution of 
40N/µl by PCR with master mix specific for (A) FR2-JH and (B) FR3-JH rearrangements. 
 
Figure 3. EBV-DNA levels in DBS. Namalwa B-cells, containing two integrated EBV 
genomes/cell, were diluted in normal PB and spotted onto DBS. EBV-DNA was quantified by 
qPCR using DNA extracted from DBS. Relationship between detected and expected EBV-DNA 
copies is shown. Each plot represents the mean value of three replicates, and the bars show standard 
deviation. 
 
Figure 4. IGH gene clonality analysis in B-CLL cases. Three representative B-CLL cases (B-
CLL#1, B-CLL#2 and B-CLL#3) were analysed using fresh whole blood in parallel with DBS cards 
with 50 µl of blotted blood. In all cases, GeneScan analysis of multiplex PCR for FR1-JH 
rearrangements revealed a monoclonal peak using DNA from fresh blood as well as from DBS 
cards. 
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General Conclusions  
Chronic immune activation, a hallmark of HIV-1 infection, may contribute to the expansion of 
EBV-infected B cells. In these studies, we described for the first time a strong association between 
HIV-1 infection, chronic immune activation and EBV load. In fact, we found a significant 
relationship between markers of microbial translocation, levels of pro-inflammatory cytokines and 
EBV-DNA levels in both HIV-1 infected adults and children, suggesting that cell activation driven 
by HIV-1 antigens may result in chronic B cell stimulation and expansion of EBV-infected B cells, 
a risk factor for the development of EBV-related malignancies. These findings were supported by a 
significant relationship between activated B-cells and EBV-DNA load observed in a subgroup of 
patients, suggesting that immune activation plays a pivotal role in the expansion of EBV-infected 
B-cells (Petrara MR et al, 2012). Persistence of plasma viremia during ART, despite 
immunoreconstitution, was frequently observed (Ometto L et al, 2002; De Rossi A et al, 2005; 
Lecossier D et al,  2001; Gilson RJ et al, 2010), and HIV-1 is known to stimulate the immune 
system, regardless of the status of  peripheral CD4 depletion/repopulation (Anselmi et al, 2007; 
Brenchley et al, 2006). In agreement with previous studies (Righetti et al, 2002; Burighel et al, 
2006), we found that EBV-DNA levels were higher in patients with a gain in CD4 lymphocytes but 
incomplete suppression of HIV-1 viremia than in patients with undetectable plasma viremia, 
regardless their CD4 cell number.  
The relationship between immune activation and EBV levels was also supported by the findings in 
HIV-1 infected children in Uganda. One of the mechanisms by which HIV-1 activates B cells 
probably involves PAMPs. These are released into circulation after HIV-1-induced cellular/tissue 
damage, engage TLRs and induce a potent immune response, involving B cells. Furthermore, 
malaria may induce B cell activation, leading to the stimulation of EBV-infected B cells via TLR-9 
engagement (Rochford R et al, 2005). In this study, we found that 16S rDNA levels, a marker of 
microbial traslocation (Jiang W et al, 2009) , significantly correlate with levels of EBV-DNA in 
ART-naive children, and EBV-DNA levels tend to be higher in children with clinical malaria. 
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Moreover, we found that EBV-DNA and 16S rDNA levels were significantly lower in children on 
ART than in those ART-naive, suggesting that treatment with ART, likely by limiting chronic 
immune activation, may prevent B cell stimulation and expansion of EBV-infected B cells. These 
observations may result of particular interest also for planning therapeutic strategies in HIV-1 
infected patients. 
We also found that NHLs are strongly associated with EBV load in peripheral blood, suggesting 
that high levels of EBV in blood might have diagnostic and prognostic relevance for the diagnosis 
and monitoring of EBV-related lymphomas. In this context we assessed that DBS sampling was 
also suitable to identify the presence of a B cell clonal population. DBS filter papers are already 
commonly used for the diagnosis and monitoring of different DNA/RNA viral loads (Snijdewind IJ 
et al, 2012). However, to date no studies investigated the quantification of EBV-DNA levels and B 
cell clonality from DBS. Previously, EBV antibodies (IgA and IgG) were tested successfully in 
eluates from DBS cards to define EBV serostatus in neuroimmunology studies (McDade et al, 
2000) and in nasopharyngeal carcinoma screening (Fachiroh J et al, 2008). While serological tests 
confirm primary infection and document remote infection, quantitative EBV-DNA assessments are 
increasingly emerging as an important laboratory tool in supporting the diagnosis and management 
of EBV-associated disease (Abbate I et al, 2011). In some regions of Africa, such as Uganda, EBV 
seroprevalence is nearly universal, with acquisition in early childhood, and there is a striking 
association of EBV with BL (Orem J et al, 2007). Therefore, EBV viral load assessment in 
peripheral blood compartments may represent an important instrument in clinical practice for the 
prevention, diagnosis and monitoring of EBV-associated diseases, even more in African children 
where EBV-associated lymphomas represent an important cause of mortality and morbidity. DBS 
sampling allows us to extend B cell clonality assay in patients with a complicated diagnosis, or 
where molecular analyses complementary to the histomorphological evaluation are not always 
available. For the first time, we showed that clonality testing can be performed from DBS, thereby 
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improving the diagnostic and monitoring capabilities of B cell lymphomas in resource-limited 
settings.  
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